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Abstract 
 
This paper examines the model of China’s biotechnology innovation. We apply the typology of 
entrepreneurial, partnership, and developmental state, to the Chinese biotechnology sector. 
Biotechnology development in China originates from state-sponsored programs. Although 
compared with the major biotechnology firm, Amgen, in the US, China’s total product sales only 
account less than the half, Chinese biotechnology research capacities experience fast growth. The 
state funding plays a crucial role in the latecomer situation. Geographically, biotechnology 
industries are concentrated in Beijing, Shanghai, Shenzhen and other major cities. The state 
promotes biotechnology development through strategic support in its ‘Medium and Long term 
S&T Development Plan’, overseas talent attraction programs, commercialization initiatives, and 
development of high-tech and science parks. However, such a model has its problems: the lack 
of sustained funding and under-developed venture capital, weak link between research and 
industry, and under-performed IP output. Faced with the funding constraint, contract research 
organizations (CROs) have recently become proliferated. Despite the strong role of state, we 
conclude that the Chinese model of biotechnology innovation is a hybrid one, rather than the 
classical one of developmental state, which combines various elements of different models.   
 
Keywords: Innovation, R&D, biotechnology, innovation model, China 
 
 
INTRODUCTION  
 
Innovation is a critical ingredient of national competitiveness, and investment in research and 
development (R&D) is closing the gap in the production of knowledge between developed and 
developing countries like China and India. Biotechnology covers agricultural biotechnology, 
healthcare biotechnology related to drug development, environmental technology and renewable 
energy. The sector is targeted by many nations as one of the new industries with the highest 
potential in the 21st century. The industry, more than others, absorbs most of the investment risk 
and it is believed to lead a new technological revolution. Biotechnology throughout the world is 
expected to accelerate and reach a new and higher stage of development. In an effort to catch up 
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with the developed world, China and India, as well as many other newly developing and 
industrializing countries, have focused on biotechnology as one of the prime strategic 
components of their innovation policies. It is generally believed that an invigorated development 
of bio-economies of these two countries will have a significant impact on the respective national 
economies and prompt an upgrading of their industrial structures.  
 
There have been extensive studies of China’s innovation system (e.g. Sun, 2002a, Wu, 2007). 
But most studies focus on the ICT sector (Wang and Lee, 2007) and high-tech parks (Walcott, 
2003; Zhou and Tong, 2003, Wei and Leung, 2005). In particular, the innovation process in 
Zhongguancun, a park based on ICT, has been studied in depth (Zhou, 2005; Liefner et al., 2006). 
Sun (2002b) found that in-house R&D was the primary source of innovation in large and 
medium-size manufacturing enterprises in China, although China also imported technologies.  
The limited effort to absorb imported technologies has become a serious barrier to fulfilling their 
potential and for upgrading China's indigenous technology capabilities. The organization of 
R&D activities in China's industrial enterprises is still fragmented with weak linkage between 
industrial R&D and the domestic technology market (Sun, 2002b). The development of ICT in 
the past decades was successful in terms of its growth rate. But the business model is copying 
foreign technology or buying technology and then assembling in China. Over years, ICT has 
experienced phenomenal growth. It appears to be more integrated in the global production 
network. Linking with global production boosted the growth of the sector. But most enterprises 
are not positioned at the upper stream of technology development, but rather acting as 
assembling and emulating MNC production. This is not to dismiss the entire ICT sector as some 
leading ICT companies are making headway into innovation. As an initial step, it might be useful 
to buy technology. The critical issue is to develop innovation capacities. China now strives to 
promote technology transfer.  
 
In contrast to extensive researches on ICT, relatively few studies are directed at China’s 
biotechnology. With the growing support of government for biotechnology research, China has 
made remarkable progress in some priority areas such as genomics and biomedicine (Chen et al., 
2007). For example, China has generated increasing publications in health biotechnology with 
average annual growth rate of 23% during the period of 1991-2002. The Chinese Academy of 
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Sciences and the top universities are the main contributions for the growth of publications. 
Beijing is the most active city in China, publishing total of 2,472 papers in genomics and 623 in 
health biotechnology. Shanghai ranked as the second and Wuhan ranked as the third in terms of 
the publications in these two areas (Science-Metrix, 2004). But the citation of Chinese 
publications is generally lower than the average level in the world. However, in the recent years, 
Chinese scientists have published many high-quality papers in the top journal in the world, such 
as Science and Nature. The significant number of high-quality publications is resulting from the 
international collaboration (Yu, 2007).  
 
Biotechnology, owing to the significant amount of investment needed, is driven initially more by 
state sponsored programs. Such an approach allows more technological orientation from the 
beginning. On the other hand, it raises a question of whether the state can sustain its investment 
in the long term, because investment in biotechnology is extremely intensive and it takes a long 
time to see economic return.  The purpose of this paper is to examine China’s biotechnology in 
the context of overall R&D strategy in China. We describe the development process of state-
sponsored biotechnology and the strength and limitation of such an innovation model. 
 
This paper is organized as follows. The next section presents the typology of three biotechnology 
innovation models in the world. Then, China’s biotechnology development is examined with 
respect to the R&D environment. We then discuss specifically the role of the state in the state-
sponsored approach. Next, we analyze the limitations of this model. Finally, we discuss recent 
changes in this state-sponsored model. Finally, in the conclusion we summarize major findings 
and compare the Chinese biotechnology innovation model with the theoretical framework.  
 
 
THREE MODELS OF BIOTECHNOLOGY INNOVATION  
 
According to Cooke et al. (2007), there are three models of innovation: entrepreneurial, 
partnership and developmental state. These innovation models are closely related to their 
respective economic development models: the liberal market-oriented, regulative and state-
centred economy. These models differ in terms of economic coordination, labour market, 
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education system, capital and financial markets, and R&D systems. We analyze China’s 
biotechnology in relation to these three models. 
 
The entrepreneurial model 
 
The entrepreneurial model is associated with the liberal market. The US liberal market is 
believed to accommodate business organization and innovation styles and strategies. Best 
coordination of the economy relies on market mechanisms. The flexible labour market allows job 
mobility between firms. Built upon a competitive ethos and economic individualism, the 
entrepreneurial model emphasizes creative or scientific novelty hedged by intellectual property 
rights. Job mobility is based on risk taking and abundant opportunity in the region (Florida, 
2002). The R&D system is characterized by strong university-based R&D. In the US, this is 
coupled with state-sponsored healthcare and defence-oriented R&D. However, the state 
programs do not substitute market-initiated selection. R&D is based on the private sector. Or 
more precisely, these programs are executed through the market. Corporate governance is based 
on private ownership (Whitley, 2000), which allows a high level of flexibility and enables shift 
response the market signals. Outsourcing and subcontracting based on competitive tendering is 
becoming popular business strategy in high-tech industry to maximize efficiency. The US model 
is a more typical entrepreneurial one, while the UK economy is considered as a variant on liberal 
market.  
 
The public-private partnership model 
 
The model is associated with rule-bound and legalistic regulation of economic activity. The state 
negotiates with and delegates social and economic functions to private associations. The business 
and industry associations are key intermediaries regulating competition between business 
partners and facilitating collaboration. This devolves into forms of self-management, which 
localize economic development and political stability (Cooke and Morgan, 1998). Many 
continental European economies, from Germany through France, Switzerland and the Nordic 
countries operate this partnership model of economic organization in which interaction occurs by 
negotiation across boundaries between otherwise divergent interests associated with government, 
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industry and labour (Cooke et al., 2007). The partnership model reinforces long-term 
cooperation among economic actors, emphasizing growth goals and the continuous exploitation 
of knowledge in established technologies. The business system usually combines a high level of 
ownership integration with strong inter-firm linkages (Whitley, 2000).  
 
Risk sharing is common between companies and there is cooperation among competitions in 
training and technical support assisted by industry associations and other intermediaries like 
chambers of commerce and industry. The capital market is credit-based, characterized by close 
links between banks and companies, including interlocking board-membership. Banks typically 
provide long-term investment with relatively low long-term risk. They are reluctant to finance 
risky, more entrepreneurial projects. The R&D system involves universities and public research 
establishments, often in cooperation. Cooperation with large and smaller enterprises also enables 
innovation gains from research findings to filter through the innovation chain rather than 
awaiting mainly entrepreneurial impulses from market signals. The governance played an 
important role through innovative policies to develop region-based industries. However, recently 
European economies began to learn from the US entrepreneurial model. For example, the 
Gate2Growth initiative, launched by the European Commission’s Directorate General Enterprise 
recently, aims to encourage innovation entrepreneurship through provide access to private 
innovation financing and tools for better knowledge exploitation. It will contribute to the strategy 
to increase the competitiveness of knowledge economy in EU (http://www.gate2growth.com/).  
 
The developmental state model 
 
In the newly industrializing economies, the developmental state model is widely practiced to 
‘catch-up’ western economies. The social context is state-centric, different from liberal and 
coordinated markets. Exemplars of the developmental state ‘big-push’ model are Japan and 
South Korea. The developmental states are plan-rational rather than market-rational, which is 
characterized by a strong, authoritarian, central government. The developmental state 
deliberately and strategically supported large enterprises and industrial competitiveness. The 
emphasis is on export-orientation. Over time, the policy shift is from trade policy, to industrial 
policy and more recently to innovation policy. There are many similarities between Japan and 
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South Korea.  But Japan is more a case of ‘state-guided’ coordination, whereas South Korea is 
‘state-organized system’. The Japanese model encourages the banking sector to support strategic 
industrial sectors; Korean model expands the scope to involve the private-sector. While the 
banking sector is similarly important in Korea, large corporations known as chaebol play an 
important role in innovation. South Korea also sees greater government deregulation of the 
industry and promotion of technology transfer in public universities to the private sector.  
 
Corporate governance in this developmental model is characterized by a high level of state-
controlled ownership and coordination (Whitley, 2000). The state controls the capital market; 
banks are mostly state-owned and provide favoured financial support for targeted large 
enterprises. Because of a low level of public funding in basic research and the weak position of 
universities in the national research system, science-based industries are weakly developed, for 
example biotechnology. Formal linkages between university and industry are underdeveloped, 
leading to a lack of academic spin-offs and technology-oriented start-ups (Lam, 2002).  
 
Comparing these three models, we find the entrepreneurial model is more flexible and responsive 
to market signals, and hence adjusts more effectively, whereas the partnership model may out-
perform liberal market ones in periods of economic stability and stable global trading patterns. 
The developmental state model can achieve certain strategic objectives and identify key sectors 
for growth and industrialization (Keeley, 2003). It can implement a long-term vision through 
top-down policy but the mechanism of coordination is more rigid.  
 
 
The developmental state and biotechnology  
 
The biotechnology sector has its specificity: it is a capital intensive sector. Some pioneer 
biotechnology companies such as Amgen and Genentech developed on the basis of scientific 
research and then commercialized their products, leading to the establishment of multi-billion 
dollar biotechnology industry. But investment in biotechnology is very intense. Compared with 
ICT, it has a longer term of capital return, and higher risk. It is extremely challenging for 
national government to sustain such a high level of investment for such a long term. From an 
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innovation idea in a laboratory to a product by the biotechnology company, it takes 12 years and 
US$802 million on average to develop a new drug (DiMasi et al., 2003). Usually there is a need 
to expand the source of investment to include venture capital. The ultimate challenge for the 
developmental state model is whether its investment in the sector is sustainable.  
 
Because of the specific nature of biotechnology development, for the latecomers, the 
developmental state model has been used to catch up biotechnology development. In 
biotechnology, Singapore represents the most aggressive developmental state model. Singapore 
Biopolis is known for the intense government input. The Biopolis is dedicated to biomedical 
R&D and designed to foster a collaborative culture among the institutions present and with the 
nearby National University of Singapore, the National University Hospital and Singapore’s 
Science Parks. The policy is to build a biotechnology cluster around foreign direct investment 
(FDI). Singapore has done well in other sectors such as petrochemicals, electronics and ICT 
using the same approach.  
 
Singapore government biotechnology initiatives started in 1987 with the establishment of the 
Institute of Molecular and Cellular Biology at the National University of Singapore. During the 
period from 2000 to 2004, investment in developing biotechnology intensified (Lim and Gregory, 
2004). Four new institutes in bioinformatics, genomics, bioprocessing and nanobiotechnology 
were developed at a cost of US$150 million. Public venture capital of $200 million has been 
committed to support start-ups and to attract FDI. A further $100 million is earmarked for 
attracting global leading corporate research centres. Internationally celebrated scientists have 
been attracted, such as Nobel laureate Sidney Brenner, Alan Colman, leading transgenic animal 
cloning scientist from Scotland’s Roslin Institute, Edison Liu former head of the US National 
Cancer Institute, and leading Japanese cancer researcher Yoshaki Ito (Cooke., 2007). Singapore 
has attracted big pharmaceutical companies such as Merck, Pfizer and Glaxo to set up 
manufacturing or clinical research service there. Its policy stimulates cluster growth as an 
offshore research and production platform targeting the burgeoning Asian market (Finegold et al., 
2004). The outstanding feature of Singapore model is its public funding in biotechnology, 
headhunting foreign talent, and stimulating indigenous spinout activity.  
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CHINA’S R&D AND BIOTECHNOLOGY DEVELOPMENT 
 
Significant increase in R&D investment 
 
China, the world’s largest emerging economy, has become the important player in R&D 
activities. China was estimated to spend over $136 billion on R&D in 2006, measured in 
purchasing power parity (PPP), only after the US (Duga and Studt, 2006; OECD, 2007a). In 
2005, Chinese investment in the total volume of PPP was equivalent to Japanese R&D 
investment, but the investment in R&D accounts was only 1.4% of GDP (Table 1). This ratio is 
still far below the US figure of 2.6% and 3.2% of Japan. Nevertheless, it is on the trajectory of 
growth, increasing from just over $17 billion in 1996 to $136 billion in 2006, even faster than the 
economy growth rate of 9-10% a year (Figure 1).   
 
[Table 1 is about here] 
 
[Figure 1 is about here] 
 
China’s investment in R&D presents two different pictures, depending on whether the real term 
or PPP is used. PPP terms will significantly inflate China’s investment. For example, in real 
terms China invested $30 billion in 2005, while PPP measure increases the figure to $124 billion, 
a four times inflation. Jakobson (2007) uses real term measure, while OECD report (OECD 
2007a) presents a picture of PPP. It is not entirely proper, in our view, to use PPP exchange rates 
to measure R&D investment, because some input in R&D such as consumables in biotechnology 
experiments are internationally priced, though salaries to researchers and scientists are low 
because of higher purchase power of Chinese currency. Even for the latter, to attract global talent, 
some living expenses are priced not according to the system of local price, for example 
international school for the children of expatriates is very pricy (at a typical annual fee of 
$20,000, compared to nominal charge of the local school). Using PPP is therefore not proper. It 
could exaggerate China’s funding capacity in R&D, as currently state funding dominants the 
capital source for R&D.  
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China’s increase in R&D investment has two implications. First, as a developing country, China 
is catching up in R&D investment. The economic growth model has moved from a simple labour 
intensive approach to knowledge investment. This increase in R&D activities is reflected in the 
recent policy emphasis on ‘indigenous capacity of innovation’, namely China needs to have its 
own IP-protected innovation and products (although the production of IP protected products 
could be achieved through joint ventures). Second, despite the significant increase in R&D 
investment, there is still a funding gap. The ratio of R&D investment to GDP is still low. This 
questions the state’s capacity as the sole funding source of long-term R&D. The Chinese 
government aims to increase R&D investment in the next decade. The target is to increase R&D 
to 2.5% by 2020 (OECD, 2007a).  
 
In biotechnology, China’s initial development was driven by the food demand of a large 
population. Its population accounts for one fifth of the world total, whereas its arable land area 
only occupies 7% of the world arable land (Chinese Academy of Agricultural Sciences, 2007), 
China’s biotechnology has emerged largely because of beneficial state policies and increasing 
funding through innovation programs. Table 2 showed the global biotechnology development 
comparison1. The key indicators on biotechnology companies show that the US has greater 
advances than Europe (EuropaBio, 2006). In the US, there are two world-leading biotechnology 
clusters: greater Boston region and San Francisco-San Diego Silicon valley. In Europe, the UK 
leads biotechnology. In the UK, Cambridge and Oxford are the main clusters. Edinburgh-
Glasgow is a new biotechnology region in Scotland. Germany and France are the after main 
biotechnology countries in Europe. In Sweden, biotechnology is growing fast with the strong 
pharmaceutical industry. In developing countries, India and China have just started their 
biotechnology development.  
 
[Table 2 is about here] 
 
                                                 
1
 To be consistent, the biotechnology companies in the table only included the main biotechnology companies, 
excluded the big pharmaceutical companies for whom biotechnology is an important, but minor part of their 
business (OECD, 2006b).  The data about China biotechnology come from different sources; some figures may be 
different depending on the definition of biotechnology. 
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In terms of the number of firms, in the US, there are nearly 2,000 biotechnology companies with 
190,000 employees, generating over $56 billion of revenue (Table 5). In 2004, the US spent over 
$28 billion in R&D. These figures are far above the numbers in other countries. In China, there 
were over 500 biotechnology firms with employment of 50,000 (CNCBD, 2007). The UK has 
the same number of companies but with less than half of employment in China. The UK showed 
more capital efficiency in terms of the ration of revenue generated from its R&D expenditure. It 
generated more than 50% revenue in the UK than Germany with similar expenditure.  
 
It was estimated that, the Chinese central government spent over US$1.8 billion in total on 
biotechnology during 2000-2005, while enterprises were estimated to spend about $60 million 
(see Figure 2). The sales of biotechnology were valued about $2.1 billion (CNCBD, 2007; 
Chong, 2005). Other sources reported that the sale of biotechnology pharmaceutical products 
grew from 10.8 billion yuan in 20012, to 16.6 billion yuan in 2002, and 22.9 billion yuan in 2003 
(CEI, 2005: 82). It was also suggested that the sale could be as high as 30 billion in 2003 by 
Shanghai Jiaotong University (SJU, 2006). According to National Development and Reform 
Commission (NDRC), the sale value reached 30.2 billion from January to August 2007 (Hu, 
2007). From this, we can estimate that the sale value may reach 45.3 billion Yuan in 2007, 
equivalent to $5.66 billion. But the definition of biotechnology is still ambiguous in China, and 
very often it is difficult to separate it from biotechnology pharmaceutical companies. In 2006, the 
largest biotech Amgen had product sales of $13.8 billion with R&D investment of $3.2 billion. 
The total product sales in China’s biotechnology only account for 41% of the sales of a single 
(but the largest global) biotech company, Amgen.   
 
R&D organization and programs  
 
In terms of biotechnology R&D management, the State Council Steering Group for Science, 
Technology and Education is a top-level co-ordination organization of the central government 
(Figure 2). The Ministry of Science and Technology (MOST) plays a prominent role, working 
with a number of ministerial level agencies – Ministry of Education, the National Natural 
Science Foundation of China (NSFC), and the Chinese Academy of Sciences (CAS). MOST 
                                                 
2
 Because the sector is relatively new, there was no statistics about the sector before 2001.  
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works with the Ministry of Agriculture (MoA) to promote the agricultural biotechnology; with 
State Food and Drug Administration to develop drug biotechnology; with Ministry of Human 
Resources (MoH) to attract talents from abroad; with Ministry of Finance (MoF) to encourage 
the innovation in enterprises. Regional governments also play a significant role to support the 
implement of the top-down innovation policy (CNCBD, 2007), in terms of regulation and 
resources, especially financial contribution for match funds. Usually regional governments are 
required to provide match 40% of total funds. For example, the local government contributes 
US$125 million to biotechnology programs (see Figure 2).   
 
[Figure 2 is about here] 
  
Enterprise, university and research institute are the three R&D performers (Figure 3). Enterprise 
is the main actor in R&D, sharing 62% of total R&D expenditure and 63% of total patent 
applications in China in 2003. It focuses on technology development and technology marketing. 
It also received the largest percentage of government funding, reaching 60%, while university 
and research institution received the similar percentage of 18% of government funding, 
according to OECD report on China’s innovation policy (OECD, 2007a). Large and medium 
firms are the major R&D players among the enterprises, while small and medium enterprises 
(SME) are active in R&D in the developed countries such as US. But in general, the enterprises 
in China, especially in ICT, have invested in importing technology more than in developing their 
own R&D capabilities because of the lack of effective incentives for R&D performers to enhance 
their innovation capacity (Chang and Shih, 2004). Industries have not broken out of the low-
value added production.  
 
[Figure 3 is about here]  
 
The public research institutions have been downsized and rebalanced in favour of universities, 
which aims to improve the research quality. A large number of research institutions have been 
reformed into private companies since the mid-1980s (OECD, 2007a).  Today, the research 
institutions started to focus more on applied research and technology transfer. They play a key 
role in mission-oriented research, mainly in the natural sciences and high-tech-related disciplines. 
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Universities are still focusing on basic research and not active in technology development and 
market. Universities are considered to have the greatest potential for developing a world-class 
research and innovation.  China’s government policy has increased the funding on universities, 
especially top rank universities such as Beijing University and Tsinghua University. The 
increased funding for R&D seems to work efficiently in terms of scientific publications, ranked 
as the fifth in 2005 in the science citation index (SCI) (OECD, 2007a). Until recent, universities 
have been urged to extend research applications and more spin-off enterprises are created within 
university, science or high-tech parks.  
 
 
In order to speed up R&D, the Chinese government has launched a series of programs (Table 3). 
Since the 1980s, China has devoted a large amount of funds and human resources in R&D 
through the program such as ‘863 program’, the ‘torch’ and ‘spark’ programs. The ‘863 
program’ was set up by MOST in 1986. The program is a national high-tech program, focusing 
on applied science. Biotechnology is at the top of several key areas. The 863 program was 
mapped with national five-year plans. Since then, the vision of biotechnology future has seen 
part of overall national modernization plan (Keeley, 2003). There are other sources of funding 
for biotechnology, including NSFC. The ‘973 program’ is for basic research (Hu and Jefferson, 
2004). But these funding sources were mainly distributed among small but well-connected 
science-policy-business network (Keeley, 2003). From 1995, the Ministry of Education decided 
to increase funding to 100 major universities to build ‘100 universities in the 21st century’, 
known as ‘211 Project’. Subsequently, from 1998, it allocated special funding to the first 34 
universities (later increased to 38) with the hope to build the first rate world research universities 
in China, known as ‘985 project’.  
 
[Table 3 is about here] 
 
 
STATE-SPONSORED R&D MODEL   
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In this section, we examine various features of state-sponsored R&D model. We first reveal the 
role of state in strategy formulation, and then discuss dominance of state funding in R&D. Next, 
we examine the state’s effort to attract overseas returnees, and finally analyze the development 
of high-tech parks as critical sub-national R&D space.  
 
Strategy formulation  
 
In terms of strategy formulation, the publication of ‘Medium- and Long- term S&T Development 
Plan’ in 2006 is a milestone of R&D development in China. The plan recognizes the need to 
develop ‘indigenous innovation’ capacity. More specifically, it aims to reduce the reliance on 
foreign patents and enhance the mastering of core technology; the plan proposes to develop 
several world-class universities and research institutions (Serger and Breidne, 2007). Chinese 
government designs strategic plan and then uses the plan to allocate funding and R&D activities 
in relevant institutes (Chang and Shih, 2004). The system of education and innovation 
encourages universities to interact with industries and promote innovation capacity. The plan 
identifies 11 key fields, 8 frontier technology fields, and 69 prioritized subjects where 
technology should be developed with Chinese ownership of IP. Biotechnology is identified as 
one of eight frontier technology. The plan recognizes the current problem of over-reliance on 
foreign technology (Jakobson, 2007). The ICT sector is more problematic, because the level of 
‘indigenous inventions’ is still low. Biotechnology sector starts from government sponsored 
programs and might provide an alternative model of innovation that fits better within the 
requirement of the Medium and Long Term S&T Development Plan. Table 4 shows the strategic 
areas in biotechnology specified in the Plan (Yu, 2007: 136). The areas include drug target 
discovery, stem cell-based human tissue engineering, to industrial biotechnology. The Plan is to 
develop an indigenous capacity, as is mostly emphasized in biotechnology.  
 
[Table 4 is about here] 
 
Dominance of state funding 
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The state funding is a critical source of biotechnology R&D, which demonstrates a marked 
dependence upon government support with limited private enterprise support. This contrasts 
markedly with the US and the UK. Private venture capital and business angels are the main 
financial resources for start-up biotechnology companies in the liberal market countries. In China, 
government programs are important source of funding. Table 5 indicated around 20-30% of “863 
program” budget have been allocated to biotechnology development in China. Also, 
biotechnology shared about one third of NSFC funding during 2001-2005 (Figure 4). This 
demonstrated the priority of biotechnology in the national innovation policy. But different from 
developmental state, the Chinese government also encourages the setting up of private 
enterprises. The nation’s public-dominated research system has also given China’s researchers a 
strong incentive to commercialize their researches. The government has the power to give 
researchers full support for their research commercialization, not only financial support but also 
regional control regulation. Local governments such as the municipality of Shanghai also play a 
critical role in the development of biotechnology through preferential policies.  
 
[Table 5 is about here]  
 
[Figure 4 is about here] 
  
This state funding model works well with China’s historical strength in basic scientific research. 
Despite a new sector, healthcare biotechnology and plant-agricultural biotechnology have a 
strong scientific research record in China. Chinese scientists have successfully developed 
chemically synthesizing bovine insulin-important in diabetes treatment in 1965. China was the 
only developing country involved in the Human Genome Project. The Chinese National Human 
Genome Centre located in Shanghai and Beijing Genomics Institutes are involved in the project. 
Through the state of art sequencing equipments, these institutes decoded the rice genome of 
predominant rice species in China. China also developed research in vaccine, diagnostics and 
therapeutics. The area covers the antibody research, notably related to severe acquired 
respiratory syndrome (SARS), gene therapy, functional genomics, and stems cells (Li et al., 
2004). In stem cells research, Chinese research institutions are working on adult as well as 
embryonic stem cells and cell reprogramming. In 2003, Shenzhen SiBono GenTech was the first 
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firm in the world to obtain a drug license for a recombinant gene therapy (Li et al., 2004). The 
product (Gendicine) is aimed at treating head and neck cancer. The clinical trial took 5 years and 
costs the company more than $9.6 million to develop, in addition to research grants from the 
government.  
 
Unlike the rest of the world in which most plant biotechnology research is financed privately 
(Huang et al., 2004), Chinese government funds almost all of its plant biotechnology research. In 
terms of plant-agricultural biotechnology, China is one of the first countries to introduce a 
commercial GM crop, and has the fourth largest GM crop area, after the US, Canada, and 
Argentina (Huang et al., 2004). Agricultural biotechnology is used as a tool to improve the food 
security of the nation, increase productivity and raise farmers’ incomes. Insect-resistant Bt cotton 
revived cotton production in China and became a successful commercialization project. Now the 
Bt cotton area accounts for about half of the total cotton area in China. MOST has increased 
plant biotechnology project funding in major research institutes from $8 million  in 1986 to $48 
million in 1999, and raising this budget by 400% before 2005 (Huang et al., 2002). The public-
dominated research system sets the agenda for research, in the important national priorities such 
as Bt cotton. Its success with Bt cotton demonstrates that plant biotechnology can have a 
significant impact on agriculture.  
 
Attracting overseas returnees 
 
A ‘Talent Strategy’ is an important issue to develop biotechnology in China. It is estimated that 
there are about 300,000 Chinese students overseas now, one-third of them are involved in the 
biotechnology field (Li et al., 2004). These expatriates are becoming as a strong driver for 
promoting biotechnology in China. Meanwhile, the government also encourages Chinese 
returnees from overseas to develop their companies with favourable public fund support. Many 
returnees may be from silicon-valley companies in technology related position.  They brought 
back the advanced technology to set up the start-up biotechnology companies in China. In 
Shanghai alone, more than 1,700 firms in all sectors have been established by returning 
professionals. For example, the director of the Beijing Genomics Institute, Dr. Huanming Yang, 
returned to China after studying and working aboard in a few countries such as Denmark, France 
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and the US (Li et al., 2004). In 2009, the Chinese government promulgated a new policy 
‘Thousands Talent’ to attract overseas returnees in high-tech sectors. The policy promises a 
series of preferential treatment, including a double increase in salaries.   
 
The strategy of attracting talents is generally effective, because China lacks the critical human 
resources in the biotechnology sector. However, the problem of these programs is that it initially 
allocated small funding to talents as start-up fund. These funds are generally small and 
insignificant. When they enter the critical stage of development, there is a problem of the lack of 
sustained funds, especially when private sector funding is not available or inadequate. Funding 
constraint still persists as a major bottleneck for these returnees to be able to fully develop their 
potentials. Again, in human resource development, the state-sponsored model shows a critical 
role of the state in formulating preferential policies.  
 
Commercializing research organizations  
 
The state sponsored model does not exclude the market. In fact, because reform is market 
oriented, the state promotes commericialization of research. Besides the establishment of 
innovation programs, the state plays a strong role in R&D commercialization (Pray, 1999; 
Keeley, 2003). There are two different routes to commercialization (Keeley, 2003). The first is to 
set up biotechnology companies based on indigenous technology. The state provides not only 
research funding but also supportive policies for developing indigenous technology. The 863 
program is a very good example for research commercialization through public and private 
partnership (Keeley, 2003). For example, Biocentury, a firm formed i  1986, was based on the Bt 
gene developed by the Biotechnology Research Institute of the Chinese Academy of Agricultural 
Science in Beijing. Biocentury's Bt gene is already in use in China, where it has earned a 
majority share of the GM cotton market. The state is the major supporter for the 
commercialization of the product. The total investment is 100 million Yuan ($12 million) 
(Keeley, 2003).  
 
The second is to commercialize through managing joint ventures (Keeley, 2003). For example, 
Monsanto, the largest agricultural biotechnology company in the world, developed joint venture 
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with local seed companies. Monsanto received the most of the profit through expensive 
technology transfer fee (Keeley, 2003). But the Chinese government has to control MNC 
because of the risk of depending on foreign technology. The management is through restricting 
the service area, service sector, venture size and share, and approval procedure. For example, the 
government restricted the sale of seeds to some provinces in order to preserve local seed firms in 
other provinces. In this aspect, the government acts more like a developmental state.  
 
Forging high-tech parks  
 
R&D activities are highly concentrated in designated national high-tech parks. In China, these 
high-tech parks are called ‘high- and new technological development zones’ (HNTDZs) (gaoxin 
jishu kaifaqu). In total there are 53 national level HNTDZs (Zhouying, 2005).Table 6 shows the 
distribution of R&D investment by province in China. Investment is concentrated in the coastal 
region, in the pattern similar to the distribution of GDP performance and the level of economic 
development. In 2006, R&D investment in Beijing, Jiangsu, Guangdong, Shanghai, Shandong, 
Zhejiang, Liaoning, Sichuan and Shaanxi exceed 10 billion Yuan (SSB, MOST and MoF, 2007). 
The overall intensity of R&D investment in China accounts for 1.42% of GDP. Beijing, 
Shanghai, Tianjin, Shaanxi, Jiangsu, Liaoning, and Zhejiang exceed the national average. In 
general, the provinces and municipalities on the coastal region are more innovative than those in 
the central and western region of China, with exception of some major municipalities such as 
Chengdu, Chongqing and Wuhan.  
 
[Table 6 is about here] 
 
Beijing concentrates the large share of basic research of public research institutes and the top 
universities, but it lacks a strong industrial base to efficiently commercialize research (OECD, 
2007a). Research commercialization has improved dramatically with the development of 
Zhongguancun Science Park in Beijing. Shanghai has built its strong biotechnology industrial 
base in the Zhangjiang High-tech Park (ZJHP), based on seven biotechnology research 
institutions and business. ZJHP is becoming an attractive location for multinational companies to 
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relocate their biotechnology R&D in China. Shenzhen has seen high-tech development with 
strong entrepreneurship since the early 1980s.  
  
In short, high-tech parks become the sub-national or regional instrument to implement state-
sponsored biotechnology innovation model. Measured in biotechnology sector in general, 
according to Prevezer and Tang (2006), there are three main clusters of biotechnology industry 
in Beijing, Shanghai and Shenzhen. The Beijing cluster has 177 firms, followed by 160 firms in 
Shanghai and 126 firms in Shenzhen. Both Beijing and Shanghai have strong bio-science 
background. In Shenzhen, some successful biotechnology companies emerged. SiBono 
developed the first gene-therapy medicine in the world. Other reports show that Beijing, 
Shanghai, Guangzhou, and Changsha as four national biotechnology bases (Liu and An, 2007). It 
is relatively difficult to identify the exact volume of production and profit in biotechnology 
because the biotechnology cannot be distinguished from a broader ‘bio-industries’ (shengwu 
chanye) according to China’s statistics. According to the Annual Report on Bio-industry in 
China, in 2007 there were a number of bio-industrial bases (NDRC-HID, 2007). Table 7 shows 
the information of some bases.  
 
[Table 7 is about here] 
 
The strength of Beijing is in its high concentration of Science academies and universities. There 
are Chinese Academy of Science, Chinese Academy of Medical Sciences, Military Medical 
Science Academy, and China Traditional Medicine Academy, plus four major universities, i.e. 
Beijing University, Tsinghua University, Beijing Traditional Medical University, China 
Agriculture University. Beijing has 31.9% of national key labs in medical sciences, and 41% of 
national key labs of life-sciences. The bio-industrial base in Beijing has its core park in 
Zhongguancun Life Science Park, Yizhuang’s Beijing ETDZ and Daxing Park. The strength of 
Shanghai comes from the concentration of research institutions and universities, especially the 
publications in the top journal such as Nature, Science and Cell, indicate the advantaged stage of 
life-science research. It has also good production capacities with major pharmaceutical MNCs, 
many of which locate their China headquarter in Shanghai. Shanghai designated ZJHP as a core 
park, and extended to Fenglin area of Xuhui District, Qingpu Industrial Park, Nanhui’s 
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Zhoukang area, and the Spark Park of Fengxian. Guangzhou is a major hub of medical research 
in southern China. It has plenty of bio resources, especially in oceanic studies. It possesses large 
domestic pharmaceutical corporations such as Baiyun and Guangzhou Pharmaceuticals. It 
develops Guangzhou Bio-island and Guangzhou Science Park as the core development area. 
Generally, the development of sub-national clusters of biotechnology is based on concentration 
of research institutes, universities and pharmaceutical industries.  
 
The outstanding feature is the development of high-tech or science parks to undertake 
development activities. Through the state-sponsored program, especially the policy to develop 
high-tech parks, biotechnology companies present an agglomerated pattern in some key 
industrial parks. In biotechnology, these clusters include Shanghai’s Zhangjiang High-tech Park, 
Beijing’s Zhongguancun Life Science Park and Yizhuang Medicine Park, and Shenzhen High-
tech Park. 
 
The development of these high-tech parks are sponsored by local states. The role of municipal 
governments is critical which can be seen clearly in the case of ZJHP. It has 168 biotechnology 
companies (including pharma-biotechnology companies) in 2006; its total output value in 
biotechnology is 4.96 billion yuan (from Zhangjiang High-tech Park website), with 8,580 
scientific researchers in 2005 (Zeng and Xiao, 2006). Shanghai municipal government in 1999 
adopted a policy called ‘Focusing on Zhangjiang’ (jujiao zhangjiang), giving a series of 
preferential policies to fiscal arrangement, human resources, project approval, land development, 
attracting foreign capital and construction of cultural facilities. The purpose of this policy is to 
concentrate the city’s capacity to establish the first-class park. Investment in Zhangjiang mainly 
came from the government, from Pudong Scientific Development Fund. In 2004, among 87 
biotechnology companies under incubation in the Park, 16 companies received special fund. In 
2005, 59 new drug development projects received 14.7 million Yuan fund (Zeng and Xiao, 2006). 
Government venture capital (Zhangjiang High-tech Ltd.) provides additional support. 
 
Because of government sponsorship, biotechnology companies in ZJHP do not form tight 
functional linkages. Research, development, and industry are still separated in function (Zeng 
and Xiao, 2006). The connection between companies is not very strong. The linkage between 
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biotechnology companies and pharmaceutical companies has not been naturally developed. The 
spill-over effect is weak. Prevezer (2008) and Ma & Fan (2008) have reached similar findings 
about the weak horizontal linkages. The MNCs firms with core technology mainly interact with 
their headquarters rather than local companies. This is especially the case for CROs. MNCs 
research labs had limited influence over biotechnology development in the park. However, recent 
effort is to develop research and industry link. An example is Fudan Zhangjiang, a company 
developed from Fudan University. Fudan University provides researchers and technology, and 
the Pudong new district government provides capital to convert research results of Fudan 
University.  
 
Except these few examples, the link among university, research institutes and pharmaceutical 
industries is generally weak. This is partially attributed to the state-sponsored R&D model, 
because the government rather than private venture capital or pharmaceutical companies is the 
major driver for biotechnology clusters. The research programs are connected with the 
government funding body in a vertical way rather than horizontally among research institutes 
and firms. In ZJHP, some research institutes have to find interested partners outside the park to 
commercialize their research. Simply putting companies and university and research institutes 
together in the same place would not automatically achieve clustering effects (Zeng and Xiao 
2006). The effect of cluster does not just depend on geographic proximity but also the 
institutional links fostered by innovation policies.   
 
LIMITATION OF STATE-SPONSORED MODEL 
Constraint on funding source  
Under the state-sponsored R&D model, biotechnology development strongly emphasizes on 
‘invention’ and less on the formation of production chain. Technological strength is not 
equivalent to industrial strength. China needs to fully exploit the use of foreign patents to 
develop production capacity. Because of the risk in drug development, it is difficult to attract 
venture capital with proof technology. In 2002, venture capital only invested US$ 420,000 in 
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biotechnology in Shanghai, only accounting for 10% of the total venture capital (SJU, 2006). 
The burst of the stock market in 2001 reduced the source of investment. Investment in 
biotechnology pharmaceutical declined, as venture capital hesitates to invest. Recently, the price 
of medicine declined, while the costs of consumables increased. From 2002, about 1,080 
enterprises attracted $5 billion from the stock market. But biotechnology only accounts for 5.2%. 
Only one product (Shenzhen Watsin Genetech Co’s rhEGF) was developed through venture 
capital. Access to finance is a major bottleneck for biotechnology companies (Hu, 2007). 
 
Globally, biotechnology industry is characterized by dominantly large companies. The total 
output value of Chinese biotech companies is below the sales of Amgen. There are too many 
small enterprises in China. China lacks flagship biotech companies such as Genentech and 
Amgen in the US. For example, for INF product, there are more than 20 companies with a 
capacity of 400 million bottles. The actual production in 2004 was 50 million bottles with sales 
value of 1.2 billion Yuan. The product in the US was sold by a single company with sales of 
$1.8 billion. But the market potential of this product in China is huge, as China has 20 to 30 
million Hepatitis B and C patients. The market share captured by the company allows the return 
of their R&D investment through high drug price control. This is why R&D can be maintained 
at a higher level in enterprises.  
 
The constraint on funding sources is evident in science parks such as Zhangjiang High-tech Park. 
Figure 5 shows the funding composition, which shows that the proportion of venture capital is 
quite limited. The funding source is heavily skewed towards the central and local governments.  
 
[Figure 5 is about here] 
 
The state sponsored model does not fully utilize China’s comparative advantage of labour cost. It 
does not help to develop China’s human resource potential. While the low cost and highly skilled 
scientists add strength to biotechnology development, China still does not have enough 
experienced experts in its ‘talent’ pool (Yu, 2007), because the development of biotechnology 
requires experienced researchers ‘who are visionaries with diverse talents, and who are capable 
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of soliciting venture investment, steering research directions, and evaluating research programs’ 
(ibid). However, various programs to attract overseas Chinese returnees help to strengthen its 
talent pool. The state sponsored approach may help to create a pool of scientists but not 
entrepreneurs with scientific knowledge. The program needs to be more industrial oriented.   
 
 
Under-performed IP-protected output 
 
Patent statistics provide a measure of innovation output. According to OECD (2006b), in 2004, 
the US had the highest number of biotechnology patents (patent application filed under Patent 
Cooperation Treaty (PCT)), accounting for 39% of the world total, while Japan and Germany are 
at the second and third position, accounting for 18% and 10% respectively (Figure 6). In terms of 
the number of patents, China only has 1.4% of the total. However, the applications for 
biotechnology patents to EPO (European Patent Office) increased remarkably in China, reaching 
the highest rate of 50% in the period from 1995 to 2003, while the US only increased by 2.4% in 
the same period.  
 
[Figure 6 is about here] 
 
Moreover, compared with the US and Japan, China saw a higher proportion of biotechnology 
inventions owned by foreign companies or co-inventors (Figure 7). The foreign ownership in 
Japan is less than 10%, and in the US the figure is about 12%. The same figure for China is as 
high as 50% (OECD, 2007b). This indicates that, on the one hand, China’s biotechnology 
development is very much internationalized; on the other, China still lacks its indigenous R&D 
capacity in biotechnology sector. Despite government funding, about half of inventions in 
biotechnology is owned by foreign partners. This means that government input has not led to the 
scale of patented products. Investment is more in basic research rather than forming a capacity of 
innovation. Because the state is the major sponsor in R&D in China as indicated in Figure 3, the 
enterprise received 60% of government funding, but the funding was mainly invested in 
importing technology rather than developing technology. In the current funding environment, a 
great portion of the funding has been diverted to building the physical infrastructures rather than 
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supporting research, which results in limited invention. In contrast to government funding, the 
multinationals are more efficient in development of new technology, especially in applied 
research using China’s advantage of strong science pool and cheaper labour cost. The low patent 
ratio also shows the limitation of state sponsored model in terms of knowledge generation which 
can be used to capture added value in production.  
 
[Figure 7 is about here] 
 
Although a few international biopharmaceutical companies come to China, many have not made 
substantial investment. Intellectual property rights (IPR) protection regulation is considered as 
one of big barriers to foreign investment to achieve the ‘win-win’ strategy. IPR plays a critical 
role in the survival of the biotechnology industry and in providing incentives for firms to invest 
in R&D (Loppacher and Kerr, 2004). Since joined in World Trade Organization (WTO) in 2001, 
China has committed to improve its IPR protection regulation.  
 
EVOVLING MODEL AND COMPARISON 
 
Evolving model of biotechnology development  
 
China’s state-sponsored R&D in biotechnology is not a static model. It adapts according to 
challenge and constraint. Because China has developed a rather active R&D market environment, 
faced with funding constraints, biotechnology firms began to seek funding outside the state 
source. One route is to play the relative strength of low labour cost. The cost of research 
scientists was estimated to be 5-10 times lower than in the US. Given relatively low cost of 
skilled researchers, available equipments and consumables and large patient population for 
expensive clinical trials, international biopharmaceutical companies began to use China as the 
basis for laboratory work. There is a wide range of opportunities for biotechnology services in 
China. Therefore China may become the ‘global laboratory’ for biotechnology development, 
built upon its experience of evolving into the world factory. There are recently three new 
changes in the biotechnology model.  
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First, Chinese research institutes began to collaborate with foreign pharmaceutical companies for 
in-licensing drug development. Chinese biotechnology companies are active in in-licensing drug 
compound discovery. They developed candidate compound in preclinical and clinical 
development. The technology focuses on gene therapy, antibodies and traditional Chinese 
medicine (TCM) modernization. TCM modernization including high-throughput screening and 
other techniques aimed at the discovery of active compounds offers China a competitive 
advantage in drug discovery.  
 
Collaboration between foreign pharmaceutical companies and Chinese biotechnology appears to 
be an important development. For example, Paris-based drug discovery company Hybrigenics 
signed a joint research project with Shanghai Institute of Material Medical to screen candidate 
compounds made in the Institute (Jia, 2005).  Based on large patient population, foreign 
companies can outsource the costing clinical trials to Chinese biotechnology companies. For 
example, US biotech Cephalon signed a deal with CRO (contract research organization) in 
Beijing Med-Pharma for clinical development of its cancer painkiller Fentora in China (Jia, 
2007). More multinationals have established research centres in China. These include Pfizer 
Pharmaceuticals in Beijing, GlaxoSmithKline in Beijing, Novartis Pharmaceutical in Beijing and 
Merck in Shanghai (Li et al., 2004). Moreover, Roche and Eli Lilly have opened R&D centres in 
China too. Although this might not bring in technology, it at least injects needed resource into 
biotechnology. Many firms developed collaborations with Chinese healthcare biotechnology 
enterprises through joint ventures. Also, through working in these joint ventures, Chinese bio-
scientists began to develop some experience in biotech entrepreneurial skills which may be 
useful for the human resource development.  
 
Second, merger and acquisition is another strategy in global biotechnology. China biotechnology 
enterprises provide manually intensive but high skilled bio-services to biotech and 
pharmaceutical companies internationally and may find an exit through acquisition. The bio-
services include nucleotide sequencing and synthesis, protein expression and library construction 
(Chervenak, 2005). For example, Beijing Genomics Institute (BGI) now provides genome 
sequencing services worldwide. Chinese companies provide lower-end bio-equipment, reagents, 
and consumables services. Some suppliers began to move into high-tech equipments and 
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analytical software. In 2004, Invitrogen Corp., the world biotechnology product and service giant, 
acquired BioAsia Co., a Shanghai-based bio-services provider, in order to expand its China 
presence both in terms of distribution and to augment its service capabilities (Chevenak, 2005). 
The successful acquisition showed an optional exit for biotechnology enterprise in China.  
 
Third, China provides a manufacturing base for global firms. The government has approved 
more than 20 biopharmaceuticals and have granted more than 130 companies with good 
manufacturing practice certification (Chevenak, 2005). The biopharmaceutical market is 
primarily generic and most domestic players have to compete on price for the same product. 
These biopharmaceutical companies show excess manufacturing capacity. With excess capacity 
and competitive price market, many Chinese biopharmaceutical manufacturers can be good 
candidates for partnership or acquisition with international biopharmaceutical companies. For 
example, Dragon Pharmaceuticals Inc. of Canada and GeneMedix Plc. of the United Kingdom 
have already established a manufacturing base in China. However, the regulation of importing 
biotech drugs in the European and US markets is strict, and thus developing an export-oriented 
biopharmaceutical manufacturing business model would be more difficult. This indicated China 
cannot solely emulate its successful export-oriental model in textile and electronics into biotech 
industry (Jia, 2007).  
 
Comparison of different innovation models  
 
Comparing the growth of biotechnology industry in the US, UK and China, we can see the 
different innovation models. Table 8 provides an initial factual comparison and Table 8 further 
compare Chinese model with the typology of three basic approaches of innovation. Because the 
US and UK models share some similarities, in discussion we focus on the comparison of US and 
China.  
 
[Table 8 is about here]  
 
In the US, biotechnology companies are usually founded on a specific technology, discovered or 
invented in research. Through convincing and attracting venture capital, the aim is to convert the 
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invention into a commercial product. This moves the technology into clinical trial, which 
requires large funding. This stage is critical to the survival of biotechnology companies. Some 
biotechnology companies are successfully purchased by big pharmaceutical companies and 
moving into the manufacturing and marketing stage, while a large number did not make it 
through this stage and demised. The mature stock market and available debt financing from bank 
make the US to be dominate player in the global biotechnology industry.  
 
In China, biotechnology started from research outputs of universities and research institutes, or 
technology brought back by overseas returnees. Some inventions are imported bought or counted 
as technological share in the company. The initial funding is from government research programs; 
for start-ups, special incubation funding is available. The government encourages spinning-off. 
When technology is tested, approval and IP are sorted out. The technology moves to the 
manufacturing stage but there are few buying-out, owing to the limited capacity of domestic 
pharmaceutical companies. For foreign manufacturing buying out, IP in overseas should be 
sorted out but this is often difficult. There is very limited exit to attract the private investors. 
Stock market just started in China and most of investors are only interested in low-risk and short-
term return sector rather than biotech sector with high-risk and long-term commitment. Debt 
financing is impossible in China. The lack of funding plus a new round of globalization in R&D 
forces the Chinese biotech sector as a whole to use the revenue generated by providing out-
sourcing services to foreign biopharmaceutical companies.  
 
Table 9 further compares the Chinese biotechnology innovation model with the typology of three 
approaches in innovation. Compared with the entrepreneurial model, the Chinese version has 
seen significant degrees of marketization of the economic system. But the intervention of the 
state is much stronger. Similar to a flexible labour market, China aims to attract overseas talent 
through higher salaries and shared rewards. In terms of private ownership and subcontracting, 
China began to see emerging private biotech companies and CROs which are driven by market 
signals. However, in other aspects, the Chinese version deviates from a liberal market model. 
The degree of state intervention is high, and the state actively formulates long-term S&T plan. 
This is similar to the developmental state model, which uses the ‘plan rationality’. Different from 
the liberal market model, the state sponsored major funding programs. Compared with the 
Page 27 of 52
http://mc.manuscriptcentral.com/cres Email: regional.studies@fm.ru.nl
Regional Studies
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 28 
partnership model, the Chinese market is less regulated and does not see much influence from 
business associations. However, the local state plays an active role in developing high-tech parks, 
by providing land, funding and infrastructure development. Different from a risk sharing and 
trust based partnership model, the Chinese model does not see a sustained and strong business 
linkage between banks and firms, horizontal link between industries, and link between university 
and industry. Compared with the developmental state model, China shares similarity in terms of 
the level of state intervention. However, the banks are less risk taking in the capital market and 
do not provide sufficient support for biotech. Rather, the state-sponsored funding becomes a 
major source. Moreover, the Chinese state-sponsored model does not see the dominance of 
public ownership. Instead, in biotech R&D, CROs become active, wholly depending upon the 
market.   
 
In sum, the Chinese model is a hybrid one – better known as a state sponsored model rather than 
a classic developmental state one. The role of the state and dominance of state funding resemble 
to the developmental state model. However, China has also seen an aggressive marketization 
process. The state also encourages labour mobility. Private biotechnology companies are 
emerging, and new CROs developed quickly. In relation to the partnership model, there is no 
strong business or local commercial organization. But the local state plays a very significant role 
in high-tech park development. In general, the link between research and industry is weak, 
because of the legacy of state dominance (Prevezer, 2008; Ma & Fan, 2008).  
 
[Table 9 is about here] 
 
Given the decentralisation of governance in China, we pay special attention to the regional level 
to see how a decentralized innovation system operates in localities. By ‘region’, we follow the 
definition by Cooke (2001), which is referred to as ‘a meso-level political unit set between the 
national or federal and local levels of government that might have some cultural or historical 
homogeneity but which at least have some statutory powers to intervene and support economic 
development, particularly in innovation’. We illustrate our observations in the Chinese case 
through three biotech clusters in China.  
 
Page 28 of 52
http://mc.manuscriptcentral.com/cres Email: regional.studies@fm.ru.nl
Regional Studies
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 29 
Shenzhen was established as a ‘Special Economic Zone’ by the central government in early 
1980s and grew rapidly as a centre for manufacturing for export in Pearl River Delta region. 
With the favourable policies, risk-taking entrepreneurship, flexible low-cost labour market, 
Shenzhen was attractive as a platform to overseas returnees in early 1990s due to its flexible 
regulation (Chen & Kenney, 2007). The advanced technologies were brought back by returnees 
from aboard, especially from USA. The favourable policies have attracted large number of 
overseas talents to set up high tech companies in Shenzhen through higher salaries, incentive tax 
and share reward. The initiative of Shenzhen as special economic zone and establishment of 
Shenzhen University suggest strong state-sponsored innovation model. Meanwhile, technology 
commercialisation in Shenzhen is more market-oriented. For example, Shenzhen manages to 
commercialize some technologies developed by Shanghai-based biotech companies. The local 
government recognised the lack of major universities in Shenzhen and proposed a policy to 
attract top universities and research institutes to set up their campus in Shenzhen. It proved to be 
an effective shortcut to overcome the shortage. Now, technology flows in Shenzhen are not only 
from aboard, but also from other cities such as Beijing and Shanghai.      
 
Shanghai strategically focuses on Zhangjiang as its biotech base. Shanghai municipal 
government designates biotechnology in ZJHP as one of the new industrial sector of Shanghai. 
The government managed to relocate the Chinese Human Genome Centre from Beijing and 
Chinese Medical University and its affiliated hospital from Shanghai Puxi to Pudong, which 
clearly reflects a model of strong state intervention (Prevezer, 2008). By 2007, there are more 
than thirty research institutions, ten foreign-owned R&D centres (e.g. Roche) and about 265 
small-to-medium size local biotech companies in ZJHP. Because of the strategy, Shanghai has 
become the first location for most of multinational pharmaceutical or biotech companies to set up 
R&D centre in China, while Beijing is more attractive for regional headquarters of multinational 
companies. Nevertheless, the state sponsored model has its limitation, as discussed earlier. 
Biotech firms cannot receive sustained investment. Many have to shift to contracted research for 
foreign firms, taking the advantage of low cost and huge patient population in China. The 
emergence of CROs suggests that biotech companies are driven by market signals rather than a 
wholly plan rationality. Recognized the need for finance, in 2006, the Shanghai Pudong New 
Area Venture Fund with $125 was established as the first policy-directed venture fund supported 
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the local government to support start-ups. The fund aimed to attract $2.5 billion venture capital 
(ZJHP, 2007). This is similar to European partnership model to share the risk for high-tech 
investment between public and private. But the market in China is less regulated than that in 
Europe where partnership model is associated with rule-bound and legalistic regulation of 
economic activity.  
 
Beijing benefits from strong science base, rich human resources from top universities, the capital 
and central government. But in biotech there was little manufacture industry and relative weak 
commercial tradition. After the S&T reform in 1985, technology enterprises known as mingying 
keji qiye were created. Most of them were spin-offs from the enterprises. Chen & Kennedy (2007) 
suggest that there was a historic linkage between these spin-offs and research institutes. However, 
the research technology commercialisation is generally weak, not like USA. These privatised 
high-tech companies are usually run by a group of scientists from universities or research 
institutes. They are good at research technology, but lack entrepreneurship and management skill. 
Biotechnology commercialisation usually requires wide ranges of talents with different skills 
including scientific, clinical, financial, legal, marketing, manufacturing, and management.  
 
To sum up, there are several advantages and disadvantages for Chinese biotechnology: the 
strategic push from the government with a clearly defined vision to set biotechnology as one of 
the frontier areas is an advantage. The environment for biotechnology start-ups is good, given 
that initial funding support and low-cost researchers are available (but the funding is not up to 
what is needed to commercialize the product; and the experienced researchers with 
entrepreneurial skills are lacking). The main disadvantage is that China lacks a mature 
pharmaceutical industry to support biotechnology commercialization. It is difficult for 
biotechnology companies to find later-stage funding sources, and the support from industry and 
venture capital is too thin. Enterprise investment in R&D is too limited. For example, 
biotechnology companies in Shanghai’s Pudong only account 41 million Yuan in 2003, 
accounting for 3% of the sale in the year, far lower than 45% investment in R&D in the US since 
1994 (SJU, 2006).   
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Biotechnology in China is still in its very initial stage, though the capacity of research is under 
formation. This means that the state needs to continue to sponsor start-ups. However, it should be 
clearly understood that access to finance needs to go beyond government sponsorship. The 
domestic market for biotechnology is under-developed at the moment, partially because of 
immature pharmaceutical industry. This may also reflect ultimately the affordability for 
expensive new drugs developed through biotechnology. Expansion toward the overseas market 
still faces much complicated and tougher IPR and approval procedure.  
 
 
CONCLUSION 
 
This paper examines the model of China’s biotechnology innovation. We applied the theoretical 
typology, namely three models of innovation, to the Chinese case. We demonstrate that the 
development of biotechnology in China is driven by the state-sponsored R&D programs. This 
innovation model was necessary at the earlier stage of biotechnology development, because it 
built upon the strength of state-funded research institutions and universities. China has the record 
of agricultural biotechnology (e.g. Bt cotton) and some healthcare biotechnology (e.g. insulin). 
This approach laid down necessary infrastructure and stimulated the clustering of biotechnology 
firms in select high-tech parks. But the Chinese model mixes up several elements in the 
theoretical models. Especially, it resorts to the market-oriented approach to R&D, despite strong 
state control and funding. A significant feature of this model is the role of local state in the 
development of high-tech parks. At the sub-national level, high-tech parks are regional 
innovation systems which combine various local advantages to form an agglomerated pattern of 
biotechnology development. The local state often uses land development mechanism to develop 
infrastructure and attract biotechnology and pharmaceuticals. This is somewhat resemblance to a 
partnership model, which suggests the importance of institution advantage in these high-tech 
parks. 
 
However, such a state-sponsored approach has its limitations. The major problem is the lack of 
sustained investment. Although China has generated a huge surplus of capital, the private 
venture capital is under-developed. In the period of economic boom, there was a strong pressure 
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to reinvest capital, but a significant amount was diverted into the real estate and stock market. 
The mechanism for private investment in high-tech has not been fully established. Related is the 
issue of IPR. Also the state funds significantly in R&D, a large proportion is used in importing 
technology licensing rather than investing in R&D. China now needs to build upon its strength of 
state-sponsorship but has to realize that the nature of biotechnology sector requires sustained 
long-term funding. It is not possible for the state alone to bear the funding responsibility.  
 
Faced with funding constraint and an actively market-oriented political economic environment, 
Chinese firms began to seek alternative models. A major departure from state sponsored R&D is 
the fast growth of CROs, building upon China’s comparative advantage of low labour and 
operational costs. Thus, China’s biotechnology innovation model is not a static one; it evolves 
with new opportunities and challenges.  
 
 
Acknowledgement: The funding support from Leverhulme Trust (F/00 407/AM) is 
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Table 1. Investment in R&D in the world 
 
Country GDP PPP* 
(billion 
USD) 
(2005) 
Percentage 
of R&D in 
GDP 
(2005) 
R&D PPP 
(billion 
USD) 
(2005) 
R&D PPP 
(billion 
USD) 
(2006) 
R&D PPP 
(billion 
USD) 
(2007) 
China 8,859.0 1.4 124.03 136.30 149.80 
US 12,192.6 2.6 319.60 328.90 335.50 
Japan 3,890.0 3.2 124.48 127.84 131.29 
Germany 2,388.6 2.5 59.68 60.21 60.75 
UK 1,933.3 1.9 36.72 37.39 38.06 
France 1,879.9 2.2 41.36 42.10 42.86 
Canada 1,033.9 2.0 20.66 21.26 21.88 
Sweden 283.5 3.9 11.04 11.33 11.64 
Israel 154.5 4.5 6.95 7.31 7.69 
Singapore 124.3 2.2 2.73 2.91 3.10 
World 50,002.0 2.0 978.34 1015.46 1051.75 
Source: Duga and Studt, 2006; OECD, 2007a. 
Note: PPP: purchasing power parity. GDP: growth domestic product. 
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Table 2. Key indicators of biotechnology companies in the world in 2004 
 
Country Companies a Employees R&D 
employees 
R&D spend 
(billion USD) 
Revenue 
(billion USD ) 
China ~500 50,000 30,000 1.80 b 2.40 
USA 1,991 190,462 79,344 28.36 56.18 
UK 457 21,134 9,384 2.11 6.12 
Germany 538 16,094 8,132 2.04 3.94 
France 223 9,142 4,246 0.80 2.97 
Sweden 138 3,942 2,579 0.50 1.16 
Source: Chong, 2005; CNCBD, 2007; EuropaBio, 2006, exchange rate at 31 Dec., 2004, 
$=0.739€. 
 
Note:  
a. The definition of biotechnology company is referred to EuropaBio, 2006. Big pharma 
companies, other major corporate and companies for whom biotechnology is an important but, 
nonetheless, minor part of their business, are not included in the above table. However, those 
may be included in other studies as biotech companies. The statistics figures about biotech may 
be varied depending on the data resources.  
 
b. The figure about China’s R&D spending is total cost during 2000-2005.
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 Table 3. R&D programs launched by the Chinese government. 
 
Program Year objective Total funding 
(Billion RMB) 
Key 
technologies 
1983 Promote the development of key 
technologies need for industrial and 
social development 
1,498 
“863” 1986 Promote R&D capabilities in high 
tech 
929 
1988 2,899 Torch 
2004 
 Commercialization of new 
technologies, entrepreneurship 
through incubators and science parks 7,131 
1986 1,475 Spark 
2004 
Diffusion and adoption of 
technologies in rural China 2,057 
National Key 
Laboratories 
1984 Basic and applied research 95 
National 
Natural 
Science 
Foundation 
1986 Basic and applied research 100 
Climbing 1992 Basic research 17 
“973” 1997 Support basic research in selected 
areas 
103 
“985” 1998 Support key research universities n.a. 
Source: Hu and Jefferson, 2004; OECD, 2007a 
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Table 4. Strategic areas of biotechnology specified by the Medium- and Long-term Science 
and Technology Development Plan. 
 
Drug target discovery Functional characterization of key and disease-related 
genes: drug target screening and validation. 
Animal and plant models 
and drug design 
Analysis and integration of bio-information; drug design 
and metabolism; computer-assisted designs, syntheses, 
and screening of compound libraries based on 
combinatory chemistry. 
Gene manipulation and 
protein engineering 
Chromosome structure and site-directed integration; 
design and manipulation of protein-coding genes; 
polypeptide chain modification; structure solving; scaled 
protein purification. 
Stem cell-based human 
tissue engineering 
Therapeutic cloning, directional differentiation; in vitro 
construction of structural organs and production; 
construction and damage repair of complex organs with 
multiple cell types. 
New generational industrial 
biotechnology 
Scaled screening of functional microbes; modification of 
bio-catalysts and industrial production; bio-conversion 
media and systems for industrial operation. 
Source: compiled from Yu, 2007. 
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Table 5 Budget of “863” programme and the share of biotechnology programs.  
 
Year Total Budget 
 (million USD) 
Share of biotechnology program 
1987-2000 712.5 26% 
2001 206.25 27% 
2002 537.5 33% 
2003 384.4 26.8% 
2004 468.75 22.6% 
2005 511.9 18.5% 
Source: Liu and An, 2007. 
Page 41 of 52
http://mc.manuscriptcentral.com/cres Email: regional.studies@fm.ru.nl
Regional Studies
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 42 
Table 6. Regional distribution of R&D investment in China in 2006 
 
Area R&D spend (billion RMB) R&D% GDP 
China 300.31 1.42 
Beijing 43.30 5.50 
Tianjin 9.52 2.18 
Hebei 7.67 0.66 
Shanxi 3.63 0.76 
Inner Mongolia 1.65 0.34 
Liaoning 13.58 1.47 
Jilin 4.09 0.96 
Heilongjiang 5.70 0.92 
Shanghai 25.88 2.50 
Jiangsu 34.61 1.60 
Zhejiang 22.40 1.42 
Anhui 5.93 0.97 
Fujian 6.74 0.89 
Jiangxi 3.78 0.81 
Shandong 23.41 1.06 
Henan 7.98 0.64 
Hubei 9.44 1.25 
Hunan 5.36 0.71 
Guangdong 31.30 1.19 
Guangxi 1.82 0.38 
Hainan 0.21 0.20 
Chongqing 3.69 1.06 
Sichuan 10.78 1.25 
Guizhou 1.45 0.64 
Yunnan 2.09 0.52 
Tibet 0.05 0.17 
Shaanxi 10.14 2.24 
Gansu 2.40 1.05 
Qinghai 0.33 0.52 
Ningxia 0.50 0.70 
Xinjiang 0.85 0.28 
Source: SSB, MOST and MoF, 2007. 
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Table 7. Information about some ‘bio-industrial bases’ in China (data from January – 
October 2007) 
 
Bio-industrial base Production value  
(billion yuan) 
Profit  
(billion yuan) 
Beijing 19.2 2.8 
Shanghai 29.3 2.7 
Guangzhou 22.5 4.7 
Shenzhen 26.6 2.3 
Changsha  24.2 2.6 
Chengdu 35.1 3.7 
 
Source: NDRC-HID (2007)
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Table 8. Comparison of biotechnology in the US, UK and China  
 
Country US UK China 
Finance  NIH funding 
Business angels 
Venture capital (VC),  
Stock market 
Debt financing 
Business angels; 
VC; 
Stock market 
 
Government funding; 
Government supported 
venture capital 
R&D investment  
(billions, USD) 
28.36 
(in the year of 2004) 
2.11 
(in the year of 2004) 
1.8  
(total from 2000 to 2005) 
Sale volume 
(billion USD) 
56.18 6.12 2.4 
R&D 
management  
NIH; NSF; Foundation BBSRC; DTI; 
Wellcome Trust 
MOST; NSFC 
Performing R&D Universities; Research 
institutes; and 
Enterprises  
 
Universities; 
Enterprises; and a few 
research institutes 
 
Universities; Research 
institutes, and enterprises,  
R&D 
collaboration  
Very strong co-
research; co-patenting; 
and co-publishing 
Co-research; co-
patenting, and co-
publishing 
Inactive link for 
technology transfer 
between universities and 
enterprises.  
Size of 
enterprises  
Dominated by a few 
big biotech such as  
Amgen and Genentech 
etc. 
SMEs Relatively concentrated in 
some biotech firms such as 
Biocentury, Sinov, Sunway 
R&D 
environment  
Universities; many 
clusters; and bio-
science parks 
University; clusters 
and few bio-science 
parks 
Universities; Shanghai 
biotechnology cluster 
Vision  Keep as global biotech 
No. 1 player 
Keep No. 1 player in 
EU  
Top 5th player in 2020 
Strength  Flexible finance 
system, 
entrepreneurship,   
Strong science base; 
regional government 
support, 
Government support; lower 
cost of the skilled labours 
Limitation Volatility of finance 
market; 
Moderate 
entrepreneurship 
culture; lack of big 
pharmaceuticals; 
Undeveloped finance 
system;  
Lack of manager talents; 
Unregulated IP protection  
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Table 9. China’s biotechnology innovation model with reference to the theoretical typology  
 
Model  Theoretical description  Chinese observation  
The entrepreneurial 
model 
- Dominance of liberal market,  
 
- flexible labour market, 
 
- private ownership, 
 
- outsourcing and subcontracting 
 
 
 
- significant marketization of the 
economic system but under state 
direction, 
 
- attracting talent through higher salaries 
and share rewards, 
 
- emerging private biotech companies  
 
- contracted research organizations 
(CROs) 
The partnership 
model 
- regulated market, 
 
- business association and chamber 
of commerce, 
 
- risk sharing,  
 
- cooperation between universities 
and public research institutes  
 
 
- less regulated market, 
 
- a significant role of the (local) state in 
developing high-tech parks, 
 
- weak link between university and 
industry and horizontal link between 
industries 
The developmental 
state model 
- planning rationale, 
 
- state bank support and greater 
state influence in the capital 
market, 
 
- state controlled ownership  
- involvement of the state in strategy 
formulation (e.g. long-term S&T plan) 
 
- dominance of state funding and S&T 
programs, 
 
- public ownership is not dominant  
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Figure 1. The growth of R&D intensity as the ratio of R&D investment to GDP in China 
during1990-2005.  
 
Source: Doug and Studt, 2006; OECD, 2007a 
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Figure 2 Biotechnology R&D management system in China. 
 
Source: modified from CNCBD, 2007.  
 
Note:  
MOST: Ministry of Science and technology 
SFDA: State Food and Drug Administration 
MOE: Ministry of Education 
NSFC: National Natural Science Foundation of China 
MOH: Ministry of Human Resources 
CAS: Chinese Academy of Sciences  
* indicates the total investment on biotechnology.  
The state council 
(Government fund: 1.8 B$* (total)) 
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Page 47 of 52
http://mc.manuscriptcentral.com/cres Email: regional.studies@fm.ru.nl
Regional Studies
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 48 
 
 
0
10
20
30
40
50
60
70
R&D
expenditure
Basic
research
Applied
research
Government
funding
%
Enterprises
Research institutes
Universities
 
 
 
 
Figure 3. The funding of three main performers of R&D in 2003 
Source: OECD, 2007a. 
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Figure 4. The life science and biotechnology funding in National Natural Science 
Foundation (NSFC) from 2001 to 2005.  
Source: compiled from Liu and An, 2007.
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Figure 5. The composition of funding source in Zhangjiang Biotech cluster  
Source: compiled from Monitor Group 2005
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Figure 6. The share and growth of global biotechnology patents. 
 
Source: OECD, 2007b 
 
*Note: PCT: Patent Cooperation Treaty; EPO: European Patent Office 
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Figure 7. Internationalization of biotechnology related inventions of selected countries, 
2001-2003.  
 
Source: OECD, 2007b 
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